GH Stock Forecast & Price Target

Guardant Health is positioned for durable fundamental outperformance because its leadership in liquid biopsy is translating into faster-than-expected reimbursement, broader guideline support, and stronger utilization across Guardant360, Reveal, and Shield. The UnitedHealthcare decision to cover Shield effective August 1, 2026, alongside ACS and NCCN inclusion, de-risks the screening franchise and should accelerate both volumes and average selling prices, while Q1’26 revenue of $302M, oncology test volume growth of 47% Y/Y, and gross margin of 65% show improving operating leverage. With $1.2B of cash, raised 2026 revenue guidance to $1.30-1.32B, and catalysts from ADLT pricing, Reveal coverage expansion, and the planned SHIELD lung readout, the company’s growth runway appears structurally intact.

Guardant Health is pressured by intensifying competition across tumor profiling, MRD, and early detection, with its core Guardant360 product representing more than 60% of sales and recent 30% Y/Y volume growth viewed as unsustainable. The company’s Shield screening franchise faces an uncertain market size and reimbursement path, while Reveal enters a crowded MRD landscape where tissue-informed testing is often preferred and Reveal Ultra later this year may still struggle to gain traction. Financially, it has burned more than $200M in cash in each of the past two years, with burn accelerating in the most recent quarter, leaving execution risk around management’s Q4 2027 breakeven goal.